Question special
Lead Moderator

Both Dr. Fowler and Dr. Flynn mentioned the challenges imposed on the PROMISE team by the evolving WHO guidelines during the trial. How was the PROMISE team able to accommodate the changing guidelines when they were inconsistent with the trial design? In an age of rapidly advancing care, what is some advice for researchers in navigating changing guidelines with ongoing research?